Investigational Drug Information for MK-1775
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
What is the development status for investigational drug MK-1775?
MK-1775 is an investigational drug.
There have been 32 clinical trials for MK-1775.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 10th 2018.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Merck Sharp & Dohme Corp., and AstraZeneca.
Summary for MK-1775
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 209 |
| WIPO Patent Applications | 216 |
| Japanese Patent Applications | 34 |
| Clinical Trial Progress | Phase 2 (2018-05-10) |
| Vendors | 86 |
Recent Clinical Trials for MK-1775
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers | National Cancer Institute (NCI) | Phase 1 |
| Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study | National Cancer Institute (NCI) | Phase 1 |
| Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for MK-1775
Top disease conditions for MK-1775
Top clinical trial sponsors for MK-1775
US Patents for MK-1775
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
